CHU Saint Pierre
Brussels, Belgium
Not recruitingPertussis
Study on How Vaccines Affect Infant Immunity to Whooping Cough in Babies Born to Vaccinated Mothers Using Diphtheria, Tetanus, and Pertussis Vaccine Combination
Verified siteRegistered drug
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
What is this trial about?
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on understanding how babies develop immunity to whooping cough, a contagious respiratory disease known for severe coughing fits. The study involves two vaccines: Vaxelis and Triaxis. Vaxelis is a combination vaccine that protects against several diseases, including diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis, and Haemophilus influenzae type b. Triaxis is a vaccine that targets diphtheria, tetanus, and pertussis with a reduced antigen content.
The purpose of the study is to identify factors that influence how well infants develop immunity to whooping cough when their mothers are vaccinated during pregnancy. The study will look at how antibodies, which are proteins in the blood that fight infections, are transferred from the mother to the baby and how the baby's immune system responds to the vaccines. Pregnant women will receive the Tdap vaccine, which is a booster shot for tetanus, diphtheria, and pertussis, to help protect their newborns from whooping cough.
Participants in the study will include pregnant women and their infants. The study will follow the infants from birth to see how their immune systems respond to the vaccines. The research aims to provide valuable insights into how maternal vaccination can protect infants from whooping cough and improve vaccine strategies for better infant health outcomes.
The research process
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
Who can join the trial?
8 criteria
- Women aged between 18 and 45 years.
- Women who are eligible for the Tdap vaccination. (Tdap is a vaccine that protects against tetanus, diphtheria, and pertussis, which is also known as whooping cough.)
- Women whose last pertussis (whooping cough) vaccination was more than 12 months ago.
- Women who are either pregnant or not pregnant.
- Infants who are 2 months old, with a margin of plus or minus 1 week. This includes both boys and girls.
- Infants who were born after 35 weeks of pregnancy.
- Infants who have a birth weight above 2.5 kg (about 5.5 pounds).
- Infants whose parents have signed a consent form, giving permission for their participation in the study.
Who cannot join the trial?
10 criteria
- Participants cannot have a history of severe allergic reactions to any vaccine.
- Participants should not have any ongoing infections or illnesses at the time of the study.
- Participants must not be taking medications that suppress the immune system, which are drugs that lower the body's ability to fight infections.
- Participants should not have any chronic illnesses that are not well-controlled, meaning their condition is not stable or managed effectively with treatment.
- Participants must not be pregnant or planning to become pregnant during the study, unless the study specifically involves pregnant women.
- Participants should not have received any other vaccines within a certain period before the study, as specified by the study guidelines.
- Participants must not have participated in another clinical trial recently, as this could affect the study results.
- Participants should not have any known immune system disorders, which are conditions where the immune system does not work properly.
- Participants must not have any history of drug or alcohol abuse, which could interfere with the study results.
- Participants should not have any mental health conditions that could affect their ability to understand or follow the study procedures.
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Verified sites
All sites with verified contact details – recruitment status may not be available; ask directly
Verified
Trial locations
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingNot finding your country?
Not sure what to do next?
Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Investigated drugs
Maternal Pertussis Vaccine
This vaccine is given to pregnant women to help protect their babies from pertussis, also known as whooping cough. When a mother receives this vaccine during pregnancy, her body produces antibodies that can be passed to the baby before birth. These antibodies help protect the newborn from pertussis in the first few months of life, before the baby is old enough to receive their own vaccinations. The goal of this vaccine in the trial is to study how well these antibodies are transferred from the mother to the baby and how they help in protecting the baby against pertussis.
What is already known about the treatment
Maternal Pertussis Vaccine – This vaccine is administered as an injection to pregnant women to protect their newborns from whooping cough, a highly contagious respiratory disease. Currently, the vaccine is well-established in medical practice and literature as a preventive measure for infants. The main therapeutic indication is to boost the mother's immune response, which in turn helps transfer protective antibodies to the baby before birth. At the molecular level, the vaccine works by stimulating the mother's immune system to produce antibodies against the pertussis bacteria, which are then passed to the infant. It is classified as a vaccine in pharmacology, specifically targeting infectious diseases.
Investigated diseases
Pertussis – Pertussis, also known as whooping cough, is a highly contagious respiratory disease caused by the bacterium Bordetella pertussis. It begins with symptoms similar to a common cold, such as a runny nose, mild cough, and fever. As the disease progresses, severe coughing fits develop, which can produce a high-pitched "whoop" sound when the person breathes in. These coughing spells can lead to vomiting and exhaustion. The disease is particularly severe in infants and young children, who may experience complications such as pneumonia. Pertussis spreads through respiratory droplets when an infected person coughs or sneezes.
Ongoing clinical trials in Pertussis
Other trials in this disease – keep exploring while you decide
Not recruiting
Pertussis
Not recruitingRegistered drug
Study of acellular pertussis vaccine and its effect on whooping cough colonization in healthy adults using controlled human infection
Registered drug
- Disease:Pertussis
- Substances:AzithromycinTETANUS TOXOID
Countries:
The Netherlands
The Netherlands- Participants:18–64 years · Healthy volunteers
- Substances:Azithromycin
- Sponsor:Stichting Radboud universitair medisch centrum
Not recruiting
Sinusitis bacterial+1
Not recruitingRegistered drugNo placebo
Study on Azithromycin for Treating Chronic Sinusitis in Adults
Registered drugNo placebo
- Disease:Sinusitis bacterialChronic sinusitis
- Substances:Azithromycin
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Azithromycin
- Sponsor:Centre Hospitalier Intercommunal Creteil
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-517893-73-00Estimated enrolment240 patientsSponsorUniversite Libre de Bruxelles
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?